• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FISHing for the Miracle of Eicosapentaenoic Acid.

作者信息

Kastelein John J P, Stroes Erik S G

机构信息

From the Academic Medical Center, University of Amsterdam, Amsterdam.

出版信息

N Engl J Med. 2019 Jan 3;380(1):89-90. doi: 10.1056/NEJMe1814004. Epub 2018 Nov 16.

DOI:10.1056/NEJMe1814004
PMID:30444682
Abstract
摘要

相似文献

1
FISHing for the Miracle of Eicosapentaenoic Acid.探寻二十碳五烯酸的神奇功效
N Engl J Med. 2019 Jan 3;380(1):89-90. doi: 10.1056/NEJMe1814004. Epub 2018 Nov 16.
2
Cardiovascular Risk Reduction with Icosapent Ethyl.二十碳五烯酸乙酯降低心血管疾病风险
N Engl J Med. 2019 Apr 25;380(17):1677. doi: 10.1056/NEJMc1902165.
3
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl.REDUCE-IT研究中心血管风险的降低归因于二十碳五烯酸乙酯中的二十碳五烯酸。
Eur Heart J. 2021 Dec 14;42(47):4865-4866. doi: 10.1093/eurheartj/ehab760.
4
Cardiovascular Risk Reduction with Icosapent Ethyl.二十碳五烯酸乙酯降低心血管疾病风险
N Engl J Med. 2019 Apr 25;380(17):1678. doi: 10.1056/NEJMc1902165.
5
Cardiovascular Risk Reduction with Icosapent Ethyl. Reply.二十碳五烯酸乙酯降低心血管风险。回复。
N Engl J Med. 2019 Apr 25;380(17):1678. doi: 10.1056/NEJMc1902165.
6
ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol.ANCHOR试验关于纯二十碳五烯酸对低密度脂蛋白胆固醇影响的结论。
Am J Cardiol. 2013 Feb 1;111(3):454-5. doi: 10.1016/j.amjcard.2012.11.035.
7
Mineral oil and icosapent ethyl may jointly explain the between arm difference of cardiovascular risk in REDUCE-IT.在REDUCE-IT研究中，矿物油和二十碳五烯酸乙酯可能共同解释了双臂之间心血管风险的差异。
Eur Heart J. 2021 Dec 14;42(47):4867-4868. doi: 10.1093/eurheartj/ehab764.
8
Authors' reply.作者回复。
Am J Cardiol. 2013 Feb 1;111(3):455-6. doi: 10.1016/j.amjcard.2012.11.036.
9
Omega-3 polyunsaturated fatty acids and cardiovascular disease: an emphasis on omega-3-acid ethyl esters 90 for the treatment of hypertriglyceridemia.ω-3多不饱和脂肪酸与心血管疾病：重点关注ω-3酸乙酯90治疗高甘油三酯血症。
Expert Rev Cardiovasc Ther. 2014 Nov;12(11):1261-8. doi: 10.1586/14779072.2014.971756. Epub 2014 Oct 16.
10
Can pleiotropic effects of eicosapentaenoic acid (EPA) impact residual cardiovascular risk?二十碳五烯酸（EPA）的多效性作用能否影响残余心血管风险？
Postgrad Med. 2017 Nov;129(8):822-827. doi: 10.1080/00325481.2017.1385365. Epub 2017 Oct 9.

引用本文的文献

1
Modern therapy of patients with lupus erythematosus must include appropriate management of their heightened rates of atherosclerotic cardiovascular events: a literature update.红斑狼疮患者的现代治疗必须包括对其动脉粥样硬化性心血管事件高发生率的适当管理：文献综述。
Lupus Sci Med. 2025 Apr 8;12(1):e001160. doi: 10.1136/lupus-2024-001160.
2
EPA Induces an Anti-Inflammatory Transcriptome in T Cells, Implicating a Triglyceride-Independent Pathway in Cardiovascular Risk Reduction.二十碳五烯酸（EPA）在T细胞中诱导抗炎转录组，提示存在一条不依赖甘油三酯的降低心血管风险途径。
JACC Basic Transl Sci. 2025 Mar;10(3):383-395. doi: 10.1016/j.jacbts.2024.09.002. Epub 2024 Oct 30.
3
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review.
高甘油三酯血症的当前及新出现的治疗选择：最新综述
Pharmaceuticals (Basel). 2025 Jan 23;18(2):147. doi: 10.3390/ph18020147.
4
Differentiating EPA from EPA/DHA in cardiovascular risk reduction.区分二十碳五烯酸（EPA）与二十碳五烯酸/二十二碳六烯酸（EPA/DHA）在降低心血管疾病风险方面的作用。
Am Heart J Plus. 2022 May 28;17:100148. doi: 10.1016/j.ahjo.2022.100148. eCollection 2022 May.
5
A Practical Approach to the Management of Residual Cardiovascular Risk: United Arab Emirates Expert Consensus Panel on the Evidence for Icosapent Ethyl and Omega-3 Fatty Acids.残余心血管疾病风险管理的实用方法：阿联酋二十碳五烯酸乙酯和欧米伽-3脂肪酸证据专家共识小组
Cardiovasc Drugs Ther. 2024 Feb 16. doi: 10.1007/s10557-023-07519-z.
6
Eicosapentaenoic Acid: between Cardiovascular Benefits and the Risk of Atrial Fibrillation.二十碳五烯酸：在心血管益处与心房颤动风险之间。
Endocr Metab Immune Disord Drug Targets. 2024;24(6):651-663. doi: 10.2174/0118715303280825231122153024.
7
The Role of Lipid-Lowering Therapy in Post-Stroke Patients: Update and Recommendations.降脂治疗在卒中后患者中的作用：最新进展与建议
Curr Atheroscler Rep. 2023 Nov;25(11):889-898. doi: 10.1007/s11883-023-01159-2. Epub 2023 Oct 26.
8
Update of the risk assessment of mineral oil hydrocarbons in food.食品中矿物油碳氢化合物风险评估的更新
EFSA J. 2023 Sep 13;21(9):e08215. doi: 10.2903/j.efsa.2023.8215. eCollection 2023 Sep.
9
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.用于一级和二级心血管预防的既定和新兴降脂药物。
Am J Cardiovasc Drugs. 2023 Sep;23(5):477-495. doi: 10.1007/s40256-023-00594-5. Epub 2023 Jul 24.
10
Marine omega-3 fatty acid supplementation and prevention of cardiovascular disease: update on the randomized trial evidence.海洋ω-3 脂肪酸补充剂与心血管疾病预防：随机试验证据的最新进展。
Cardiovasc Res. 2023 Jun 13;119(6):1297-1309. doi: 10.1093/cvr/cvac172.